Differential Expression of BARD1 Isoforms in Melanoma

Genes (Basel). 2021 Feb 23;12(2):320. doi: 10.3390/genes12020320.

Abstract

Melanoma comprises <5% of cutaneous malignancies, yet it causes a significant proportion of skin cancer-related deaths worldwide. While new therapies for melanoma have been developed, not all patients respond well. Thus, further research is required to better predict patient outcomes. Using long-range nanopore sequencing, RT-qPCR, and RNA sequencing analyses, we examined the transcription of BARD1 splice isoforms in melanoma cell lines and patient tissue samples. Seventy-six BARD1 mRNA variants were identified in total, with several previously characterised isoforms (γ, φ, δ, ε, and η) contributing to a large proportion of the expressed transcripts. In addition, we identified four novel splice events, namely, Δ(E3_E9), ▼(i8), IVS10+131▼46, and IVS10▼176, occurring in various combinations in multiple transcripts. We found that short-read RNA-Seq analyses were limited in their ability to predict isoforms containing multiple non-contiguous splicing events, as compared to long-range nanopore sequencing. These studies suggest that further investigations into the functional significance of the identified BARD1 splice variants in melanoma are warranted.

Keywords: BARD1; RNA-Seq; melanoma; nanopore sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alternative Splicing / genetics*
  • Cell Line, Tumor
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Melanoma / genetics*
  • Melanoma / pathology
  • Nanopore Sequencing
  • Protein Isoforms / genetics*
  • RNA-Seq
  • Tumor Suppressor Proteins / genetics*
  • Ubiquitin-Protein Ligases / genetics*

Substances

  • Protein Isoforms
  • Tumor Suppressor Proteins
  • BARD1 protein, human
  • Ubiquitin-Protein Ligases